Dulaglutide
Brand: Trulicity
A once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction — including in people without established heart disease.
Trulicity is FDA-approved (2014) for type 2 diabetes and (2020) for reducing major adverse cardiovascular events, the first GLP-1 drug indicated for that in both primary- and secondary-prevention populations.
What it is
Dulaglutide is a GLP-1 receptor agonist built by fusing two GLP-1 analog peptides to a modified antibody (IgG4 Fc) fragment. That large, protected structure resists breakdown and slows clearance, giving it a roughly five-day half-life and enabling once-weekly injection from a pre-filled, needle-hidden pen designed for ease of use.
What it’s approved or studied for
Dulaglutide is FDA-approved for type 2 diabetes (2014) and for cardiovascular risk reduction (2020). The cardiovascular indication is notable because it covers people both with and without established heart disease — the first GLP-1 drug approved for primary as well as secondary prevention.
What human evidence exists
The AWARD program is a large, randomized set of trials that established glycemic benefit and supported the higher 3.0 mg and 4.5 mg doses (AWARD-11). The REWIND outcomes trial (2019) then showed a roughly 12% reduction in major cardiovascular events in a broad diabetes population that was mostly free of prior cardiovascular disease — the finding behind its primary-prevention indication. Glycemic control and cardiovascular risk reduction are Grade A. Weight loss is a real but modest secondary effect (Grade B): consistent across trials, but not an approved obesity use and smaller than the newer agents deliver.
The major unknowns
Dulaglutide’s weight effect is modest, so it is not a first choice when substantial weight loss is the goal. As with the class, durability after stopping and the lean-mass cost of any weight lost are open practical questions, and long-term data continue to accumulate.
Most important safety considerations
Gastrointestinal effects lead the side-effect profile and ease with gradual dose escalation. The rodent-based thyroid C-cell boxed warning applies; a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. Pancreatitis and gallbladder disease are uncommon but recognized. This is a research summary, not medical advice — decisions belong with a clinician.
Evidence by outcome
Each outcome is graded on its own evidence — a compound can be strong for one use and unproven for another. See how we grade.
Approved and consistently proven to lower HbA1c. — The AWARD program showed reliable HbA1c reductions (roughly 1.3–1.8% depending on dose) versus placebo and active comparators. AWARD-11 established the higher 3.0 mg and 4.5 mg doses.
Reduces major cardiovascular events across a broad diabetes population. — REWIND (Lancet 2019) randomized adults with type 2 diabetes — most without established cardiovascular disease — and showed a roughly 12% reduction in major adverse cardiovascular events, driven largely by fewer non-fatal strokes.
Modest weight loss — a consistent secondary effect, not an obesity indication. — Weight reduction is a reproducible secondary outcome across the AWARD trials (a few kilograms, more at higher doses), but dulaglutide is not approved for chronic weight management and its effect is smaller than semaglutide's or tirzepatide's.
Not a benefit — some lean mass is lost with fat.
Safety
Common adverse effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
Serious risks
- Pancreatitis (uncommon)
- Gallbladder disease
- Thyroid C-cell tumors (seen in rodents; boxed warning)
- Acute kidney injury with dehydration
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Known hypersensitivity to dulaglutide
References